BEP3
01 Feb 2021
Trial Summary
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours
Acronym:
BEP3
ACTRN/NCT /ethics:
NCT02582697
Ethics: 384.14
Scientific title:
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Sponsor / Cooperative group:
University of Sydney
Trial & Patient Characteristics
| Cancer Type | Neuroendocrine |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 11- 45 years |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2014-02-14 |
| Anticipated End Date | 2023-07-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |
| Hospital | The Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 70742342 |
| Principal Investigator | - |
| Recruitment Status | Recruitment on Hold |